抗高尿酸血症药物研究进展  

Research progress on anti-hyperuricemic drugs

作　　者：刘永贵[1] 赵丽嘉[1] 崔艳丽[1] 贺星[1] 沈雪砚[1] 陈常青[1] 

机构地区：[1]天津药物研究院医药信息中心,天津300193

出　　处：《现代药物与临床》2015年第3期345-350,共6页Drugs & Clinic

摘　　要：痛风是一种代谢性疾病,危害严重,近年来患病率呈上升趋势。尿酸排泄减少或生成增多所致的高尿酸血症是痛风的主要病因,而高尿酸又与多种疾病密切相关。降低血尿酸水平是治疗痛风,预防痛风复发的重要措施。目前,抗高尿酸血症药物主要有3类,分别是黄嘌呤氧化酶抑制剂、尿酸盐阴离子转运蛋白1(URAT1)抑制剂和尿酸氧化酶类似物。对现有抗高尿酸血症药物的现状以及研究进展进行总结,希望对其研发提供参考。Gout is a metabolic disease, and does serious harm to human beings. In recent years, gout prevalence rate assumes upwards trend. Hyperuricemia caused by decreased uric acid excretion or increased formation of uric acid may account for gout. While high uric acid is closely related to various diseases. Therefore reducing blood uric acid level is the important measure to treat gout and prevent the recurrence of gout. So far, there are three kinds of anti-hyperuricemic drugs, including xanthine oxidase inhibitors, Urate anion exchanger 1 （URAT1） inhibitors, and urate oxidase analogues. The present situation and research progress of anti-hyperuricemic drugs are reviewed in this paper, in order to provide a reference for the development of anti-hyperuricemic drugs.

关 键 词：痛风 高尿酸血症 抗高尿酸血症药 黄嘌呤氧化酶抑制剂 URAT1抑制剂 尿酸氧化酶 

分 类 号：R977[医药卫生—药品]